In a analyze in breast cancer cells, The mix of lapatinib, a dual HER2/neu and EGFR tyrosine kinase inhibitor, with INK128 prevented both of those HER2 and HER3 phosphorylation induced by INK128 and developed synergistic induction of mobile Loss of life in various HER2-optimistic mobile lines resistant to trastuzumab and lapatinib. In vivo3-O-p-Cou